AAIPharma Services, Cambridge Major Laboratories Name Executive VP - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AAIPharma Services, Cambridge Major Laboratories Name Executive VP



AAIPharma Services, a provider of pharmaceutical analytical testing, product development, and manufacturing services, and Cambridge Major Laboratories, a provider of pharmaceutical API development and manufacturing, have appointed Jeff Yuen as executive vice-president, global quality. Yuen has served as food and drug investigator at the State of California’s, Department of Health Services and was a Commander in the US Public Health Service at FDA. He also was GMP auditor, GMP advisor or FDA advisory committee member at National Nutritional Foods Association, Dietary Supplement, and BIOCOM. After leaving the FDA, he led an independent firm focused on FDA compliance and regulatory consulting for the dietary supplement, pharmaceutical, and biotechnology industries.

Source:AAIPharma Services

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here